Regimen Reference Order – CUTA – cetuximab

ARIA: CUTA - [cetuximab]

Planned Course: Every 14 days until disease progression or unacceptable toxicity
Indication for Use: Squamous Cell Cancer, Locally Advanced or Metastatic

CVAD: At Provider's Discretion

Proceed with treatment if:
Blood work at provider's discretion: not required to proceed with treatment

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA – cetuximab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycles 1 and 2		
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medication(s) before starting cetuximab		
cetuximab	500 mg/m^2	IV over 2 hours (administered undiluted) Doses greater than 1200 mg must be infused over 2.5 hours *Use 0.2 or 0.22 micron filter* **Alert:* Pharmacy to ensure final volume on label* **Nursing Alert:* IV tubing is primed with cetuximab*
Cycles 3 and Onwards		
cetirizine	10 mg	Orally 30 minutes prior to cetuximab
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medication(s) before starting cetuximab		
cetuximab	500 mg/m^2	IV over 2 hours (administered undiluted) Doses greater than 1200 mg must be infused over 2.5 hours *Use 0.2 or 0.22 micron filter* **Alert:* Pharmacy to ensure final volume on label* **Nursing Alert:* IV tubing is primed with cetuximab*
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles

- No blood work is required to proceed with treatment
- CBC, serum creatinine, urea, liver enzymes, magnesium, calcium and albumin as per Physician Orders
- Clinical assessment of cetuximab-related skin toxicity

Cycles 1 and 2

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline, after one-hour observation and as clinically indicated
- Observe patient for 1 hour after cetuximab infusion. Full vital signs prior to discharge

Cycle 3 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- For patients with no prior reactions to cetuximab, no observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not
- For patients who have had a previous reaction to cetuximab, observe patient for 1 hour after cetuximab infusion. Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Sunscreen	Minimum SPF 15 (PABA free, zinc oxide or titanium dioxide preferred)	Apply topically a broad-spectrum sunscreen liberally 30 minutes before going outdoors. Reapply every 2 hours and after swimming
Moisturizing lotion	Fragrance-free	Apply topically to face, hands, feet, neck, back and chest daily in the morning on rising and ***as needed***
In the event of a cetuximab-induced skin rash:		
doxycycline	100 mg	Orally twice daily as directed by clinic
hydrocortisone cream	1%	Apply topically daily at bedtime to face, hands, feet, neck, back and chest as directed by clinic

DISCHARGE INSTRUCTIONS

- Warn patients of the possibility of a late onset reaction to cetuximab as reactions may occur several hours after infusion or with subsequent infusions
- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to use Recommended Support Medications

ADDITIONAL INFORMATION

- cetuximab can cause hypomagnesemia
- cetuximab causes dermatological and nail changes
- cetuximab can cause interstitial lung disease, pneumonitis and exacerbation of pre-existing fibrotic lung disease
- Administration site restrictions are in place for cetuximab. Dose 1 of cetuximab should only be administered at CCMB MacCharles or Tache in Winnipeg